Fresh Data Pushes Microbiome Pioneer Ferring Closer To Approval Line
RBX2660 Filing Before Year-End
Executive Summary
The promise of microbiome-based therapeutics to treat a variety of diseases has become a hot topic and the first to get to market will be targeting Clostridioides difficile infection. Ferring and its subsidiary Rebiotix are in pole position.
You may also be interested in...
MaaT’s FDA Woes Highlight Rocky Regulatory Path For Microbiome-Based Therapies
The French firm's lead microbiome therapy has been on clinical hold in the US for a year and continuing concerns about MaaT's 'pooling' approach (mixing donations from multiple donors) suggests the wait to restart trials will not be a short one.
Pfizer Holds Out Hope For C. Diff Vaccine Despite Clinical, Commercial Failures
Pfizer’s Clostridioides difficile vaccine candidate missed a Phase III primary endpoint but the company may seek a path forward based on secondary endpoints even after past failures in the field.
Six Key Infectious Disease New Drug Launches To Look Out For In 2022
In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.